Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience

Kittika Poonsombudlert,Sarah Mott,Benda Miller,Prajwal Dhakal,Anthony Snow,Sarah Hornberg,Ratdanai Yodsuwan,Christopher Strouse,Hira Shaikh,Margarida Magalhaes‐Silverman,Grerk Sutamtewagul
DOI: https://doi.org/10.1111/ejh.14199
2024-03-22
European Journal Of Haematology
Abstract:A remarkably high rate of post‐transplant relapse in patients with TP53‐mutated myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) calls to question the utility of allogeneic stem cell transplant (HSCT). We, therefore, performed a retrospective analysis to compare the outcomes between HSCT (N = 38) versus non‐HSCT (N = 45) approaches. Patients in the HSCT cohort were younger (median age 63 vs. 72) while patients in the non‐HSCT cohort more commonly had complex karyotype with chromosome 17 aberrancy and 5q deletion (p
hematology
What problem does this paper attempt to address?